{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:43:53Z","timestamp":1785519833562,"version":"3.56.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1692","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved vonoprazan (Voquezna \u2013 Phathom), a potassium-competitive acid blocker, for healing and maintenance of healing of all grades of erosive esophagitis and relief of associated heartburn in adults. Vonoprazan is also available copackaged with amoxicillin (Voquezna Dual Pak) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection in adults.<\/jats:p>","DOI":"10.58347\/tml.2023.1692b","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T20:16:44Z","timestamp":1702325804000},"page":"203-205","source":"Crossref","is-referenced-by-count":3,"title":["Vonoprazan (Voquezna) for Erosive Esophagitis"],"prefix":"10.58347","volume":"65","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"37151","published-online":{"date-parts":[[2023,12,25]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T20:16:45Z","timestamp":1702325805000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1692b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":0,"journal-issue":{"issue":"1692","published-online":{"date-parts":[[2023,12,25]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2023.1692b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,25]]}}}